NMD4C Hiring a Postdoc to Develop Spinal Muscular Atrophy Decision Aid

We are looking to fill a postdoctoral position to develop a tool to support decisions of families and clinicians in selecting a treatment plan for individuals affected by SMA.

This fellowship is based at the University of British Columbia (UBC) in collaboration with Muscular Dystrophy Canada (MDC) and the NMD4C in a well established and dynamic environment fosters professional development and interdisciplinary research collaborations.

With the support of the research team, the postdoctoral fellow will:

  • Acquire training on the Ottawa Decision Aid Framework
  • Conduct a decision need assessment among SMA leading clinicians and families
  • Develop a tool aid
  • Write a grant proposal for implementation and assessment of the SMA tool to CIHR

For further information please read the full job posting.

The NMD4C is looking for a postdoctoral fellow to develop a decision aid for SMA.

Read next...

New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada

We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy

NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.

06-2026 NMD4C AFC Program Launch & September Workshop

Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop

The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.